Zenas BioPharma (ZBIO)

• Market cap: $1.25B
• 1 day: -3.37%
• 5 days: -11.3%
• 1 month: -13.22%
• 3 months: -37.03%
• 6 months: 27.36%
• Year to date: -32.67%
• 1 year: 175.56%
• 5 years: 27.99%
• 10 years: 27.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Employees: 130